C. Todd Nichols serves as the Senior Vice President and Chief Commercial Officer at Alkermes, a global biopharmaceutical company focused on developing innovative medicines for patients with serious chronic diseases. In his role, Nichols is responsible for overseeing the company's commercial strategy and operations, including sales, marketing, and market access. His leadership has been instrumental in driving the successful launch and growth of Alkermes' key products, such as VIVITROL for the treatment of alcohol and opioid dependence, and ARISTADA for schizophrenia. Prior to joining Alkermes in 2010, Nichols held various leadership positions in the pharmaceutical industry. He spent over a decade at Pfizer, where he served as Vice President of Sales and Marketing for the company's Primary Care Business Unit. During his tenure at Pfizer, Nichols played a key role in the successful launch of several blockbuster medications, including Lipitor and Celebrex. Before Pfizer, he worked at Bristol-Myers Squibb, where he held positions of increasing responsibility in sales and marketing. Nichols holds a Bachelor of Science degree in Business Administration from the University of Richmond. Throughout his career, he has been recognized for his strategic vision, strong leadership skills, and ability to build high-performing teams. At Alkermes, Nichols has been a driving force behind the company's growth and success, helping to establish the company as a leader in the development and commercialization of innovative treatments for complex diseases.